Log in to search using one of your social media accounts:

 

Rockville-based cancer therapy company Cytimmune Sciences in fundraising mode
The company is working on a therapy for pancreatic cancer using nanotechnology. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 20, 2017 Category: Health Management Authors: Tina Reed Source Type: news

Suicide molecules kill any cancer cell
(Northwestern University) A super assassin hidden in every cell forces the cell to commit suicide if it becomes cancerous, reports a new study, the first to identify molecules to trigger a fail-safe mechanism that may protect us from cancer. The mechanism -- RNA suicide molecules -- can potentially be developed into a novel form of cancer therapy. Cancer cells treated with the RNA molecules never become resistant to them because they simultaneously eliminate multiple genes that cancer cells need for survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 19, 2017 Category: Cancer & Oncology Source Type: news

Gilead new cancer therapy wins FDA approval — with $373,000 tag
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 18, 2017 Category: Pharmaceuticals Source Type: news

Researchers release the brakes on the immune system
(University of Bonn) Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural 'brakes' in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes. The study, which involved colleagues from Hamburg and W ü rzburg, could pave the way for more effective cancer therapies. It is being published in the journal Cell Reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2017 Category: Cancer & Oncology Source Type: news

Immunotherapy Side Effects: New Global Guidelines for Nurses Immunotherapy Side Effects: New Global Guidelines for Nurses
Immunotherapy has revolutionized cancer therapy, but these drugs have unique and sometimes life-threatening adverse events, as outlined in the new guidelines.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 16, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Vanderbilt researchers find novel mechanism of resistance to anti-cancer drugs
(Vanderbilt University Medical Center) Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported Oct. 16 in Nature Medicine, suggest a strategy for overcoming this resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news

US NIH launches $215m Partnership for Accelerating Cancer Therapies
The US National Institutes of Health (NIH), along with 11 biopharmaceutical companies, has launched a $215m five-year public-private research collaboration to advance new cancer immunotherapy strategies for more patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 15, 2017 Category: Pharmaceuticals Source Type: news

NIH Partners With 11 Drugmakers to Accelerate Cancer Therapy Research NIH Partners With 11 Drugmakers to Accelerate Cancer Therapy Research
The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body's immune system to fight cancer.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

A range of substances with antitumor properties was synthesized at RUDN University
(RUDN University) Scientists from RUDN University have synthesized a number of new cytotoxic substances - the ones that can damage cells. In the future the results of the study can be used in cancer therapy. The compounds were obtained by domino reaction, a successive formation of several new chemical bonds. The study was published in the Synthesis journal (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 13, 2017 Category: Cancer & Oncology Source Type: news

U.S. NIH, 11 drugmakers partner to accelerate cancer therapy research
(Reuters) - The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

PhRMA, member companies and NIH create public-private partnership for immuno-oncology
The rapid pace of scientific advances has helped usher in anew era of medicine for cancer patients over the last decade. This morning, the National Institutes of Health (NIH) took asignificant step in advancing this new era by partnering with PhRMA and nine of its member companies to create the Partnership for Accelerating Cancer Therapies (PACT), a five-year research collaboration totaling $215 million as part of the Cancer Moonshot initiative. This public-private partnership will be managed by the Foundation for the National Institutes of Health. (Source: The Catalyst)
Source: The Catalyst - October 12, 2017 Category: Pharmaceuticals Tags: Research and Development cancer Source Type: news

NIH partners 11 drugmakers to accelerate cancer therapy research
(Reuters) - The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body's immune system to fight cancer. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

NIH, 11 biopharmaceutical companies partner to speed development of cancer immunotherapy strategies
(NIH/Office of the Director) The National Institutes of Health and 11 leading biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers -- standardized biological markers of disease and treatment response -- to advance new immunotherapy treatments that harness the immune system to attack cancer. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - October 12, 2017 Category: International Medicine & Public Health Source Type: news

Cleveland Clinic researchers reveal biomarker for guiding prostate cancer treatment
(Cleveland Clinic) Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies. The studies, published in the Oct. 12 issue of JAMA Oncology, suggest that men who inherit this variant would benefit from a personalized treatment plan that targets specific hormonal pathways. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 12, 2017 Category: Cancer & Oncology Source Type: news

Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development
TAMPA, Fla., Oct. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Intezyne Technologies, a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it closed an oversubscribed $10M Series A Preferred round lead ... Biopharmaceuticals, Oncology, Venture Capital, Personnel Intezyne Technologies, Cancer Resistance Pathway (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 6, 2017 Category: Pharmaceuticals Source Type: news

'Smart' immune cells: Emerging cancer therapy research boosted with NIH award
(University of California - Davis) Assistant Professor Sean Collins, Department of Microbiology and Molecular Genetics in the UC Davis College of Biological Sciences, has received a $1.5 million award from the National Institutes of Health to advance the development of 'smart' immune cells for therapies to treat cancer and other diseases. The five-year NIH Director's New Innovator Award aims to provide new insight into how to engineer immune cells to control their recruitment and response to tumors. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 5, 2017 Category: Biology Source Type: news

Colorectal Cancer Therapy Gets a Tune-up: ESMO 2017 Colorectal Cancer Therapy Gets a Tune-up: ESMO 2017
Although not a year for big advances in colorectal cancer, exciting research with current standards was presented at ESMO 2017.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

A new approach to cancer drug discovery
Scientists at The Scripps Research Institute (TSRI) have developed and demonstrated a promising new strategy for the discovery of novel anti-cancer therapies. The TSRI scientists, collaborating with scientists at Pfizer, used their new approach to find small-molecule inhibitors of a protein that is important for the growth of non-small-cell lung cancers (NSCLCs). These cancers represent about 85 percent of lung cancers and are relatively insensitive to drug treatment. (Source: World Pharma News)
Source: World Pharma News - September 29, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

A new approach to cancer drug discovery
(Scripps Research Institute) Scientists at The Scripps Research Institute (TSRI) have developed and demonstrated a promising new strategy for the discovery of novel anti-cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 29, 2017 Category: Cancer & Oncology Source Type: news

Pfizer helps pump $103M into startup to develop new cancer therapies
A New York startup has been spun-out of Pfizer to develop clinical-stage experimental therapies. Nascent medicine company SpringWorks Therapeutics completed a $103 million series A round led by the New York-based pharma giant with the help of Bain Capital, OrbiMed and LifeArc (formerly known as MRC Technology). Pfizer (NYSE: PFE) granted SpringWorks the rights to help develop four drugs or t herapies that treat various conditions, including post-traumatic stress disorder and cancer. Another New… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 26, 2017 Category: Biotechnology Authors: Anthony Noto Source Type: news

New approaches in targeted cancer therapy
(University of Cologne) In a large-scale testing procedure, scientists from Cologne University Hospital have explored the effects of more than 1,500 substances on different kinds of cancer cells. The results from this study are a fundamental prerequisite for the development of new therapies for NMC, an aggressive cancer which is often lethal. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 26, 2017 Category: Cancer & Oncology Source Type: news

Pfizer helps pump $103M into startup to develop new cancer therapies
A local startup has been spun-out of Pfizer to develop clinical-stage experimental therapies. Nascent medicine company SpringWorks Therapeutics completed a $103 million series A round led by the New York-based pharma giant with the help of Bain Capital, OrbiMed and LifeArc (formerly known as MRC Technology). Pfizer (NYSE: PFE) granted SpringWorks the rights to help develop four drugs or t herapies that treat various conditions, including post-traumatic stress disorder and cancer. Another New York-based… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 25, 2017 Category: Pharmaceuticals Authors: Anthony Noto Source Type: news

Photoacoustic imaging and photothermal cancer therapy using BR nanoparticles
(The Korea Advanced Institute of Science and Technology (KAIST)) Sangyong Jon, a professor in the Department of Biological Sciences at KAIST, and his team developed combined photoacoustic imaging and photothermal therapy for cancer by using Bilirubin (BR) nanoparticles.The team expects this research, which shows high biocompatibility as well as outstanding photoacoustic imaging and photothermal therapy, to be an appropriate system in the field of treatment for cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 25, 2017 Category: Cancer & Oncology Source Type: news

Hearst invests $75 million in Moffitt's M2Gen
M2Gen, a Moffitt Cancer Center subsidiary that uses big data to find ways to treat cancer, is receiving a $75 million equity investment from Hearst. The partnership will help accelerate the discovery of innovative cancer therapies and improve care for patients nationwide, Hearst said in a press release. The press release did not disclose the amount of the investment, but a Moffitt spokeswoman confirmed it was $75 million. Hearst invests in c ompanies working to improve and advance health care,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 20, 2017 Category: Health Management Authors: Margie Manning Source Type: news

Hearst invests $75 million in Moffitt's M2Gen
M2Gen, a Moffitt Cancer Center subsidiary that uses big data to find ways to treat cancer, is receiving a $75 million equity investment from Hearst. The partnership will help accelerate the discovery of innovative cancer therapies and improve care for patients nationwide, Hearst said in a press release. The press release did not disclose the amount of the investment, but a Moffitt spokeswoman confirmed it was $75 million. Hearst invests in c ompanies working to improve and advance health care,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 20, 2017 Category: Biotechnology Authors: Margie Manning Source Type: news

Penn researchers identify new target, develop new drug for cancer therapies
(University of Pennsylvania School of Medicine) Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to target that enzyme resistant to treatment. Researchers were able to use this finding to develop a drug that successfully inhibits tumor growth of melanoma as well as pancreatic and colorectal cancer in mice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Mesothelioma Clinical Trials Involve Gene Therapy
Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen rece...
Source: Asbestos and Mesothelioma News - September 19, 2017 Category: Environmental Health Authors: Matt Mauney Tags: CAR T cell therapy checkpoint blockade chimeric antigen receptor T cell therapy Dr. Andy Haas Dr. Prasad Adusumilli Dr. Scott Gottlieb FDA Commissioner gene therapy cancer gene therapy for mesothelioma immunotherapy clinical trial mali Source Type: news

Cancer Treatment Can Affect Your Food Preferences
TUESDAY, Sept. 19, 2017 -- Cancer therapies often change patients'sense of taste, which may affect what they like to eat, according to a nutrition expert. " Increased taste sensitivities are more common than a muting of taste, " said Catherine... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 19, 2017 Category: General Medicine Source Type: news

New cancer care 'passport' for London ’s nurses launched
A “cancer care passport” has been launched for the capital’s oncology specialist nurses, so they can demonstrate they are qualified and competent to deliver systemic anti-cancer therapy (SACT). (Source: Nursing Times)
Source: Nursing Times - September 15, 2017 Category: Nursing Source Type: news

Debugging a cancer therapy
(Source: ScienceNOW)
Source: ScienceNOW - September 14, 2017 Category: Science Authors: Kiberstis, P. A. Tags: Medicine, Diseases twis Source Type: news

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2',2'-difluorodeoxycytidine) into its inactive form, 2',2'-difluorodeoxyuridine. Metabolism was dependent on the expression of a long isoform of the bacterial enzyme cytidine deaminase (CDDL), seen primarily in Gammaproteobacteria. In a colon cancer mouse model, gemcitabine resistance was induced by intratumor Gammaproteobacteria, dependent on bacterial CDDL expression, and abrogated by cotreatment with the antibiotic ciprofloxa...
Source: ScienceNOW - September 14, 2017 Category: Science Authors: Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., Thaiss, C. A., Reuben, A., Livny, J., Avraham, R., Frederick, D. T., Ligorio, M., Chatman, K., Johnston, S. E., Mosher, C. Tags: Medicine, Diseases reports Source Type: news

GSK bets on pioneering cancer therapy with Adaptimmune deal
LONDON (Reuters) - GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

$61M payday: GSK exercises option for Adaptimmune's T-cell cancer therapy
CEO: 'This is a very exciting day.' (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 7, 2017 Category: American Health Authors: John George Source Type: news

Zika virus may be useful in treating brain tumours
Conclusion This is an interesting piece of research that shows how knowledge in one field of medicine can sometimes be applied to another field with surprising results. But it's important to be realistic about the stage of research. This is very much a "proof of concept" study, and tests on cells, tissues and mice don't necessarily translate into a safe and effective treatment for humans. The study has several limitations, but the fact the treatment so far hasn't been tested on humans is the most important. For one thing, Zika virus doesn't naturally infect mice, so researchers had to use a specially engineered v...
Source: NHS News Feed - September 6, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Merck buys German immuno-oncology company in deal valued at up to $554M
Merck entered into a deal Wednesday to buy a German cancer immunotherapy company in a deal valued at up to $554 million. Merck will make an upfront payment of $137.3 million to Munich-based Rigontec. The deal also includes an additional $417 million in potential milestone payments. The transaction is subject to certain closing conditions. Immunotherapy is a rapidly expanding field in cancer therapy that seeks to im prove the ability of a patient’s own immune system to identify and destroy tumors. Rigontec’s… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 6, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

Profit on $475,000 Novartis Cancer Drug Could Be a While Coming Profit on $475,000 Novartis Cancer Drug Could Be a While Coming
Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

A parent ’s guide to clinical trials
Children with life-threatening conditions, such as cancer, are often candidates for clinical trials. What are they? Which factors should parents weigh in determining whether enrolling in one is a good option for their child? Dr. Steven DuBois, director of the Advancing Childhood Cancer Therapies Clinic at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, answers questions about clinical trials. What are clinical trials? Why are they important? Clinical trials are systematic, scientific investigations of new drugs or therapies for a specific disease. Through clinical trials, we have taken many fatal ped...
Source: Thrive, Children's Hospital Boston - September 1, 2017 Category: Pediatrics Authors: Irene Sege Tags: Ask the Expert Research and Innovation clinical trial Dana-Farber/Boston Children's Cancer and Blood Disorders Center Dr. Steven DuBois Source Type: news

Profit on $475,000 Novartis cancer drug could be a while coming
ZURICH (Reuters) - Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even. (Source: Reuters: Health)
Source: Reuters: Health - August 31, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

US regulator signs off on new $475,000 cancer therapy
Novartis says price is ‘appropriate’ and below independent estimates (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - August 30, 2017 Category: Pharmaceuticals Source Type: news

FDA OKs first-of-its-kind T-cell cancer therapy developed by Penn & CHOP
The Food and Drug Administration approved a personalized cellular therapy treatment for leukemia developed by researchers at the University of Pennsylvania and Children ’s Hospital of Philadelphia. The T-Cell therapy, which will be marketed by Novartis as Kymriah, was OK'd as treatment for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory, or in second or later relapse. In 2012, Penn and Novartis — a Swiss dr ug company that has its U.S headquarters… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 30, 2017 Category: American Health Authors: John George Source Type: news

Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal
Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Merck collaborates with angiex to speed clinical readiness of new cancer therapy
Merck, a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up's ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibodydrug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1. (Source: World Pharma News)
Source: World Pharma News - August 29, 2017 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Pathway's power to boost, halt tumors may be promising cancer therapy target
(Penn State) A protein, called inositol-requiring enzyme 1 -- IRE1 -- may serve as a key driver in a series of molecular interactions that can both promote and, paradoxically, inhibit tumors in certain types of cancers, such as non-melanoma skin cancers, according to a team of molecular biologists. They add that this pathway's dual power may make it a tempting target for future research on the design of new types of anti-cancer therapeutics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 29, 2017 Category: Cancer & Oncology Source Type: news

Researchers discover new immunotherapy combination effective at killing cancer cells
(University of Calgary) Researchers at the University of Calgary recently discovered an immunotherapy that uses existing cancer drugs in a whole new way. 'What we found is a combination of cancer therapies that complement each other in helping the immune system clear the cancer,' says Doug Mahoney, PhD. 'Our results suggest that we've been looking at these cancer drugs the wrong way -- as tumour-targeting drugs -- instead of what we now feel is their most important biological role: as immune stimulating therapy.' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 29, 2017 Category: International Medicine & Public Health Source Type: news

Anti-inflammatory therapy cuts risk of lung cancer
In most clinical trials for cancer therapy, investigators test treatments in patients with advanced disease. But a recent cardiovascular secondary prevention study has given researchers a unique opportunity: to explore the effectiveness of giving a drug to patients before cancer emerges. At the European Society of Cardiology meeting, Paul M. Ridker, MD, director of the Center for Cardiovascular Disease Prevention at BWH, and colleagues presented findings from CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study). (Source: World Pharma News)
Source: World Pharma News - August 28, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Gilead to buy Kite for promising cancer therapies in $12 billion deal
(Reuters) - Gilead Sciences Inc agreed to buy Kite Pharma Inc in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to generate billions. (Source: Reuters: Health)
Source: Reuters: Health - August 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Anti-inflammatory therapy cuts risk of lung cancer
(Brigham and Women's Hospital) In most clinical trials for cancer therapy, investigators test treatments in patients with advanced disease. But a recent cardiovascular secondary prevention study has given researchers a unique opportunity: to explore the effectiveness of giving a drug to patients before cancer emerges. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news

Mass. General team reports first response of central nervous system tumor to CAR T-cells
(Massachusetts General Hospital) In a letter to the New England Journal of Medicine, a Massachusetts General Hospital research team reports a remarkable treatment response in a patient participating in a clinical trial of a novel immune-system-based cancer therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 28, 2017 Category: Cancer & Oncology Source Type: news

Alternative Medicine Alone Leads to Lower Cancer Survival
Cancer patients who opt for alternative therapy instead of conventional medicine significantly decrease their chances of survival, according to researchers at Yale School of Medicine. Although the popularity of alternative medicine continues to grow, a recent study published in the Journal of the National Cancer Institute found survival rates significantly reduced for those who use it as first-line therapy. Conventional cancer treatments — chemotherapy, surgery and radiation — still produce a much better chance of survival. Mesothelioma was not included in the study, but the findings are relevant to this rare ...
Source: Asbestos and Mesothelioma News - August 23, 2017 Category: Environmental Health Authors: Matt Mauney Tags: acupuncture cancer Alternative medicine alternative mesothelioma treatment alternative therapy survival alternative vs conventional medicine breast cancer colon cancer Conventional cancer treatments Dr. David Gorski Dr. Skyler Johnson Source Type: news